Der Calypte-Thread
26.06.12 13:30
#51
buran
kurslich festgehangen
im Chart ersichtlich,nun wird's zeigen welchen Weg das kleine Schwarze einschlagen wird
spannend immer und immer wieder,oh Glaskugel bitte nichts vorsagen,ich brauch den Kick
danke Buran
spannend immer und immer wieder,oh Glaskugel bitte nichts vorsagen,ich brauch den Kick
danke Buran
06.07.12 12:36
#52
buran
Calypte
schliesst drüben bei den Amis immer wieder top - also ich lass mich hier überraschen was die Kaugummilutschers vorhaben ;-)............kalkuliertses RISIKO
10.07.12 10:21
#53
buran
wie gesagt RISIKO
ist nicht gleich Risiko oder Übermut - alles knallhart kalkuliert
13.07.12 20:17
#54
buran
+3,15%
stehen zu Buche - "Skorpion:Risiko-Bereitschaft" eben im Radio (weil ich bin Skorpion)
13.07.12 20:18
#55
buran
#54 Ergänzung
Thread:
Perf. seit Threadbeginn: +40,00%
Calypte ist voll im Rennen...da kommt richtig was *kreisch*
Perf. seit Threadbeginn: +40,00%
Calypte ist voll im Rennen...da kommt richtig was *kreisch*
05.09.12 12:19
#61
buran
unser aller Erstaunen ist immer wieder groß
alle Tage sind gute Kurse zu sehen,so muss es sein und weitergehen
http://www.calypte.com/about-us/
http://www.calypte.com/about-us/
05.09.12 12:20
#62
buran
Calypte Biomedical Corporation
develops in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection, sexually transmitted diseases and other chronic diseases. Our innovative product line includes both point-of-case rapid tests and traditional ELISA/EIA diagnostic tests.
beakers
Calypte also offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers seeking to develop and optimize immunodiagnostic assays. These unique products are based on technologies developed by Calypte scientists and are used throughout our range of in vitro diagnostic tests.
Founded in 1988, Calypte is a pioneer in non-blood-based HIV antibody testing. We’re the first and only company to earn approval from the U.S. Food and Drug Administration for a urine-based HIV-1 antibody-screening test and supplemental Western blot.* Today, our Aware™ family of rapid oral fluid, blood and urine HIV tests offers unrivalled HIV 1/2 testing flexibility in a non-laboratory setting.
Calypte is also the licensed manufacturer of a unique, quantitative enzyme immunoassay developed by the U.S. Centers for Disease Control and Prevention (CDC) that can discriminate between recent and established HIV-1 infections. Designed for use in epidemiology, the Aware™ BED™ EIA is the only practical way to determine HIV-1 incidence — how quickly HIV is spreading in a given population — rather than prevalence. Since its introduction in 2004 (formerly under the name BED HIV-1 Incidence EIA), the Aware™ BED™ EIA has gained widespread favor with government institutions and HIV intervention programs worldwide as a tool for better allocating resources, measuring program success and targeting HIV hot spots.
Working through a network of national and regional distributors as well as through our on-line Life Sciences web-portal (www.calyptelifesciences.com), Calypte continues to broaden the reach of its products. We plan to launch a new line of rapid HIV antibody tests in the United States and other developed nations using a novel lateral flow platform technology and are working to complete development of a nucleic acid-based diagnostic testing platform. We also remain committed to bringing new products to developing regions where the need is acute for accurate, innovative HIV testing methods.
To meet this demand with maximum quality and efficiency, we’ve expanded our research and pilot manufacturing capacity in Portland and opened offices in Geneva and the United Arab Emirates. We’ve also added manufacturing capacity through a contract with an ISO-certified manufacturer in Thailand and a managed ISO-certified joint venture in China. Publicly held, Calypte trades on the OTCBB under the symbol “CBMC.”http://www.calypte.com/about-us/
beakers
Calypte also offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers seeking to develop and optimize immunodiagnostic assays. These unique products are based on technologies developed by Calypte scientists and are used throughout our range of in vitro diagnostic tests.
Founded in 1988, Calypte is a pioneer in non-blood-based HIV antibody testing. We’re the first and only company to earn approval from the U.S. Food and Drug Administration for a urine-based HIV-1 antibody-screening test and supplemental Western blot.* Today, our Aware™ family of rapid oral fluid, blood and urine HIV tests offers unrivalled HIV 1/2 testing flexibility in a non-laboratory setting.
Calypte is also the licensed manufacturer of a unique, quantitative enzyme immunoassay developed by the U.S. Centers for Disease Control and Prevention (CDC) that can discriminate between recent and established HIV-1 infections. Designed for use in epidemiology, the Aware™ BED™ EIA is the only practical way to determine HIV-1 incidence — how quickly HIV is spreading in a given population — rather than prevalence. Since its introduction in 2004 (formerly under the name BED HIV-1 Incidence EIA), the Aware™ BED™ EIA has gained widespread favor with government institutions and HIV intervention programs worldwide as a tool for better allocating resources, measuring program success and targeting HIV hot spots.
Working through a network of national and regional distributors as well as through our on-line Life Sciences web-portal (www.calyptelifesciences.com), Calypte continues to broaden the reach of its products. We plan to launch a new line of rapid HIV antibody tests in the United States and other developed nations using a novel lateral flow platform technology and are working to complete development of a nucleic acid-based diagnostic testing platform. We also remain committed to bringing new products to developing regions where the need is acute for accurate, innovative HIV testing methods.
To meet this demand with maximum quality and efficiency, we’ve expanded our research and pilot manufacturing capacity in Portland and opened offices in Geneva and the United Arab Emirates. We’ve also added manufacturing capacity through a contract with an ISO-certified manufacturer in Thailand and a managed ISO-certified joint venture in China. Publicly held, Calypte trades on the OTCBB under the symbol “CBMC.”http://www.calypte.com/about-us/
19.09.12 01:36
#64
buran
hier noch einmal tolle Zahlen
Aktienanzahl 700,2 Mio. (Stand: 13.04.12)
Marktkap.§5,60 Mio. $
und +33,33% sind in Sack und Tüten *grinz*
Marktkap.§5,60 Mio. $
und +33,33% sind in Sack und Tüten *grinz*
21.11.12 10:53
#65
buran
Nasdaq-Schluss 20-11-2012
Calypte Biomedical 0,0035 $ +16,66% buran und danke
11.01.13 14:34
#66
buran
geht klar hier
0,0029 $ +31,81% +0,0007 $
In Euro: 0,0022 € | Nasdaq OTC Other, 09.01.13
In Euro: 0,0022 € | Nasdaq OTC Other, 09.01.13
14.01.13 18:49
#68
buran
jo und der Ticker voll aktiv #67
Zeit Kurs Stück
16:23:45 0,30 $ 60.000
16:23:35 0,29 $ 10.000
15:30:18 0,25 $ 19.000
..scheiss die Wand an iss Börse schön
16:23:45 0,30 $ 60.000
16:23:35 0,29 $ 10.000
15:30:18 0,25 $ 19.000
..scheiss die Wand an iss Börse schön
14.01.13 18:59
#70
buran
danke für das Kompitent *schäm* #69
Du bist aber n ganz Knuffigen Du ..hooaaa
14.01.13 19:09
#71
buran
Du Don
haste nochmehr sonne Kompitente für die Tante buran? ..das liest sich runter wie'n Sahnetörtchen was Du da schreibst ..Schlingelchen
>>> und immer hier noch gucken:: Dow macht 13.495 Zählerpunkte
Tante buran
Ps ey Don ..ich stell ne Kerze in's Fenster hooaaaaa
>>> und immer hier noch gucken:: Dow macht 13.495 Zählerpunkte
Tante buran
Ps ey Don ..ich stell ne Kerze in's Fenster hooaaaaa
14.01.13 19:46
#74
buran
ja ..sie riecht so gut
..hier mal fix die Auslandstelefonnummer:: US1317226058

